# Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression — In Vivo Validation

Federal contract opportunity, via Kontrakk.

- **Agency:** HEALTH AND HUMAN SERVICES, DEPARTMENT OF.FOOD AND DRUG ADMINISTRATION.FDA OFFICE OF ACQ  GRANT SVCS
- **Notice ID:** b587aac3a76a4528bd4298359acde021
- **Solicitation number:** 75F40126Q00382
- **Notice type:** Presolicitation
- **Set-aside:** No Set aside used
- **NAICS:** 541714
- **Location:** Nationwide
- **Posted:** August 26, 2026
- **Response deadline:** September 10, 2026
- **View on Kontrakk:** https://kontrakk.com/contracts/b587aac3a76a4528bd4298359acde021
- **View on SAM.gov:** https://sam.gov/workspace/contract/opp/b587aac3a76a4528bd4298359acde021/view

## Description

Full description available on SAM.gov: https://sam.gov/workspace/contract/opp/b587aac3a76a4528bd4298359acde021/view

## Points of contact

- Kimberly Pennix · kimberly.pennix@fda.hhs.gov · 2404029703 (primary)
- Ian Weiss · Ian.Weiss@fda.hhs.gov · 3017965728 (secondary)